

# BLOOD BULLETIN

DECEMBER 2014

PROVIDED BY



In conjunction with America's Blood Centers®

---

## HEPARIN INDUCED THROMBOCYTOPENIA

---

By Minh-Ha Tran, DO, Associate Clinical Professor of Pathology & Medicine, University of California, Irvine; Associate Medical Director, Transfusion Medicine Services, UC Irvine Health. The author discloses no conflicts of interest.

### BACKGROUND

Heparin-induced thrombocytopenia (HIT) occurs in two major forms – Type I, which is non-immunologic and associated with mild transient thrombocytopenia, and Type II, caused by an immunologic reaction that induces a declining platelet count and an intense prothrombotic state. Type II HIT, the focus of the remainder of this review, will henceforth be referred to as simply “HIT.”

HIT more commonly occurs in association with unfractionated heparin (UFH; 1-5% incidence) than with low molecular weight heparin (LMWH; 0.1-1% incidence), and is more frequent among surgical patients (1-5%) than medical patients (0.8-3%).<sup>1</sup>

### PATHOPHYSIOLOGY

Released during platelet activation, Platelet Factor 4 (PF4) forms complexes with UFH or LMWH on the surface of platelets. In some individuals the resultant neoantigen becomes the target of a pathologic IgG antibody (HIT-Ab). This induces the formation of a Heparin-PF4-HIT-Ab immune complex that attaches to FcγIIa receptors on the platelet membrane, resulting in platelet activation and elaboration of platelet microparticles.<sup>2-5</sup> In such instances the presence of warfarin, which leads to decreased production of Protein C, can exacerbate the HIT-hypercoagulable state.<sup>6</sup>

### CLINICAL FEATURES AND DIAGNOSIS

Thromboembolic complications occur in 50-75% of affected individuals and involve the venous more commonly than the arterial vasculature.<sup>6</sup> Events may include deep venous thrombosis (DVT), pulmonary embolism (PE), catheter-related thrombosis, limb ischemia, stroke, myocardial infarction, cerebral venous sinus thrombosis, adrenal vein thrombosis, warfarin-induced limb gangrene plus skin necrosis, and necrotic skin lesions at sites of heparin injection. Such complications can be accentuated by continued administration of heparin.<sup>7</sup>

The diagnosis of HIT should be considered when platelet counts decline in proximity to UFH/LMWH exposure. Variations of HIT include: (1) “rapid onset HIT” (platelet decline less than 4 days after *initiation* of heparin; median of 10.5 hours – up to 30% of cases),<sup>8,9</sup> (2) “classic HIT” (platelet decline 4 to 14 days after *initiation* of heparin – at least 65% of cases),<sup>8,9</sup> and (3) “delayed onset HIT” (platelet decline 9-14 days after *discontinuation* of heparin – 2-3% of cases).<sup>7</sup> Of key utility to clinicians is what is referred to as the “4T’s”

### Key Points

- HIT-reactive antibodies may reduce platelet counts and initiate an intense prothrombotic state.
- Enzyme immunoassay (EIA) testing is associated with high false-positive rates; consider basing preliminary diagnosis on pretest probability assessment (4T’s); a strongly positive EIA result and positive serotonin release assay confirm the diagnosis.
- In patients with HIT, cessation/avoidance of unfractionated and low molecular weight heparins is insufficient to prevent thrombosis; initiate treatment with a non-heparin alternative (in most cases argatroban).
- If warfarin was utilized prematurely, then reversal with Vitamin K and initiation/continuation of a non-heparin anticoagulant is advised.
- Warfarin initiation should await normalization of platelet counts and overlap with use of non-heparin anticoagulant.

scoring system – see Table – in which a score  $\leq 3$  denotes a high negative predictive value for HIT (0.998; 95% CI, 0.97-1.00), whereas a score of 6-8 indicates a high probability that HIT is present.<sup>10</sup> Interestingly, despite the reduced platelet counts associated with HIT, bleeding manifestations are rare, and some experts suggest the presence of bleeding supports a non-HIT etiology for the thrombocytopenia.<sup>11</sup>

Testing for HIT involves selection of either a serologic (i.e., PF4-dependent EIA) or functional platelet assay (i.e., <sup>14</sup>C Serotonin Release Assay, SRA, believed to be the “gold standard”). For most facilities, the SRA is a send-out test. The degree of PF4-dependent EIA (i.e., PF4/heparin or PF4/polyvinyl sulfonate) reactivity – reported in optical density (OD) units – is predictive for SRA reactivity.<sup>12</sup> With weakly positive EIA results (e.g., 0.40-1.40 OD units) there is a low probability ( $\leq 5\%$ ) for a strong-positive SRA result. At OD values of  $> 1.40$  and  $\geq 2.00$ , the probability for a positive SRA increases to 50% and 90%, respectively.<sup>12</sup> A negative PF4-dependent EIA virtually excludes the diagnosis of HIT.<sup>11</sup>

### TREATMENT AND MANAGEMENT DECISIONS

Treatment is initiated when the clinical likelihood is intermediate to high (i.e., a 4T’s score of  $\geq 4$  – see Table) and

(continued on next page)

should not be delayed while awaiting test results. All sources of UFH/LMWH exposure (including line flushes, dialysis catheter lock solutions, and DVT prophylaxis) must be stopped and treatment must be initiated with a non-heparin anticoagulant due to the high residual risk for thromboembolic complications.<sup>11,13</sup> Also, warfarin, if its use has been initiated prematurely, should be stopped and its effect reversed with Vitamin K.<sup>14</sup>

In most patients, argatroban is initiated at a dose of 2mcg/kg/min and titrated to maintain a therapeutic PTT of 1.5 to 2.5 the patient’s baseline level.<sup>11</sup> Other treatment options include danaparoid (where available), bivalirudin (particularly in cardiac surgery), and fondaparinux. Treatment is continued until the platelet count has reached a stable plateau, ideally ≥ 150,000/μL. Most patients will be transitioned to warfarin at this time with a period of five days of overlapping therapy being recommended. A hematology consultation should be considered during this transition phase.

Two case series have failed to demonstrate a link between platelet transfusions and thromboembolic complications in patients with HIT, though data are insufficient to conclude absolute safety.<sup>15,16</sup> Lastly, the reader is encouraged to review other excellent references with regard to the management of patients who have recovered from HIT and who once again require anticoagulation.<sup>11,14</sup>

**CONCLUSION**

HIT represents a drug-induced thrombocytopenia marked by reductions in the platelet count and initiation of an intense thrombophilic state. Patients may be diagnosed clinically using the 4T’s scoring system; HIT EIA and SRA testing provide additional diagnostic support. Treatment is initiated using an appropriate, alternative anticoagulant and maintained until the platelet count has normalized.

**References**

1. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. NEJM 2006;355:809-17.
2. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68:95-6.
3. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/ thrombosis are specific for platelet

- factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-8.
4. Visentin GP. Heparin-induced thrombocytopenia: Molecular Pathogenesis. Thromb Haemost 1999; 82: 448-56.
5. Davenport A. Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin induced thrombocytopenia in hemodialysis. Am J Kidney Diseases 2009;54:361-74.
6. Warkentin TE. Chapter 25: Heparin-induced thrombocytopenia, in: Kitchens CS, Kessler CM, Konkle BA, eds. Consultative Hemostasis and Thrombosis, 3<sup>rd</sup> Ed. 2013, Elsevier Saunders, Philadelphia, PA.
7. Bartholomew JR, Begelman SM, Almahameed A. Heparin-induced thrombocytopenia: principles for early recognition and management. Cleveland Clinic Journal of Medicine 2005;72(s1):S31-S36.
8. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. NEJM 2001;344:1286-92.
9. Warkentin TE, Kelton JG. Heparin induced thrombocytopenia (letter to editor). NEJM 2001;345:619-20.
10. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012;120:4160-7.
11. Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood 2012;119:2209-18.
12. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF-4 dependent enzyme immunoassays. Journal of Thrombosis and Haemostasis 2008;6:1304-12.
13. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-851.
14. Linkins L-A, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia. antithrombotic therapy and prevention of thrombosis, 9<sup>th</sup> Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl):e495S-e530s.
15. Refaai MA, Chuang C, Menegus M, Blumberg N, Francis CW. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost 2010;8:1419-21.
16. Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion 2008;48:2128-32.



Blood Bulletin is issued periodically by America’s Blood Centers. Publication Committee Chair: Chris Gresens, MD. The opinions expressed herein are opinions only and should not be construed as recommendations or standards of ABC, ABC SMT Committee, or its board of trustees. Publication Office: 725 15th St., NW, Suite 700, Washington, DC 20005. Tel: (202) 393-5725; Fax: (202) 393-1282; E-mail: [abc@americasblood.org](mailto:abc@americasblood.org). Copyright America’s Blood Centers, 2014. Reproduction is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

**Table: The 4 T’s Method for Estimating – Prior to Immunologic Testing – the Probability for HIT:** Up to two points are assigned to each of the four categories listed below and these scores are then totaled. *Low*, *Intermediate*, and *High* probabilities for HIT correspond to scores of 1-3, 4-5, and 6-8, respectively.<sup>10</sup>

Category	Score = 2 Points	Score = 1 Point	Score = 0 Points
Degree of thrombocytopenia	> 50%* decrease in platelet count to nadir ≥ 20,000/μL	30-50%* decrease in platelet count <u>OR</u> nadir of 10,000-19,000/μL	< 30%* in platelet count <u>OR</u> nadir < 10,000/μL
Timing of thrombocytopenia following first heparin dose	Clear onset during Days 5-10 <u>OR</u> within 1 day in patient given heparin during past 30 days	Possible onset during Days 5-10 but not certain (e.g., missing platelet count data) <u>OR</u> onset after Day 10 <u>OR</u> onset within 1 day in patient given heparin 31-100 days ago	Onset prior to Day 5 and no heparin exposure within past 100 days
Evidence of thrombosis or other problems	New confirmed thrombosis, skin necrosis, <u>AND/OR</u> systemic reaction associated with IV bolus of UFH	Progressive or recurrent thrombosis, non-necrotic skin lesions, <u>AND/OR</u> suspected (but unproven) thrombosis	None
Existence of other possible causes for thrombocytopenia	No other apparent cause	Possible alternate cause	Definite alternate cause

\*Determined from peak platelet count following initiation of heparin therapy.